Patients with sickle cell disease and suspected COVID‐19 in a paediatric intensive care unit

Abstract

Concern has been raised for patients with sickle cell disease (SCD) and the new viral infection severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as patients with SCD are particularly prone to infectious diseases and acute chest syndrome (ACS). Although case reports have been published to describe coronavirus disease 2019 (COVID-19)-related ACS in adult patients,1-4 paediatric data are lacking. We conducted a single centre retrospective observational study, between 1 March and 15 April 2020, in the paediatric intensive care unit (PICU) of Necker Hospital for Sick Children in Paris (tertiary care, SCD reference centre, regional reference centre for emerging infectious diseases). All patients with SCD with suspected COVID-19 admitted to the PICU were eligible for the study. Confirmed COVID-19 was defined as a positive SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) from a nasal swab. ACS was defined according to the Vichinsky's criteria5 Computed tomography (CT) scans were not mandatory. A nasal swab was collected in the first 12 h of the patients’ arrival and SARS-CoV-2 RT-PCR was performed. The local Ethics Board (Necker Enfants-Malades) waived the need for approval. All patients were informed about the study. From 1 March to 15 April 2020, 12 children with SCD were included, aged 5–17.5 years. RT-PCR for SARS-CoV-2 was performed in 11of the 12 children and was positive in four. All four patients were SS patients, with no glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients 2 and 4 were on hydroxyurea (HU), and patient 2 had also been on a transfusion programme for 3 years before he was switched to HU and received desferasirox. Patient 2 had also undergone splenectomy and had experienced previous ACS episodes. The baseline haemoglobin (Hb) and fetal haemoglobin (HbF) levels, when available, are listed in Table I. The patients presented COVID-19 symptoms from 2 to 12 days before hospital admission (Fig 1). All four patients experienced chest pain, with patient 4 also experiencing shoulder and back pain, all requiring intravenous morphine. The maximum daily dose of morphine received ranged from 0.6 to 1.5 mg/kg/day. All four patients presented with ACS. Oxygen requirement before NIV was between 1 and 6 l/min, with a respiratory rate from 32 to 50 breaths/min. Maximum venous partial pressure of CO2 (PCO2) was 50 mmHg for all four patients (only one patient had an arterial blood gas). All patients received early NIV on arrival in the PICU, with worst fraction of inspired oxygen (FiO2) from 30 to 46%, positive expiratory pressure (PEP) between 5 and 7 cmH2O, and inspiratory pressure between 10 and 15 cmH2O. NIV was administered continuously at first and then sequentially. Patients received from 58 to 128 h of NIV during their PICU stay. All patients had favourable respiratory outcome with no apparent respiratory distress remaining after discharge from the PICU. All patients presented some unilateral or bilateral inferior lobe consolidations. Patients 3 and 4 also had CT scans with mixed ground glass (with or without halo sign) and consolidation opacity (Data S1). Mild pleural and pericardial effusions were also present on the CT scans. Patient 4 had an extensive left lower and sub-segmental right pulmonary embolism. All patients had a high fever (>39.5 °C) and various degrees of inflammation. None of the patients received steroids. Biological markers of inflammation and thrombosis are listed in Table I. All patients received cefotaxim and azithromycin according to the local protocol. No patient received antiviral therapy or hydroxychloroquine. One patient (patient 4) with substantial inflammation (Table I) received tocilizumab (8 mg/kg/dose, one intravenous dose) at day 16 of COVID-19 (day 4 in the PICU), with good tolerance and a favourable outcome. That same patient had a high heart rate, anxiety and high D-dimers, and presented with a segmentary pulmonary thrombosis on CT scan performed at day 13 of COVID-19 (day 1 in the PICU), which was treated with enoxaparin. Patients 2 and 3 received RBC transfusion in their local hospitals before their transfer to the PICU, patient 4 received RBC transfusion on day 16 of COVID-19 (day 4 in the PICU) for an Hb level at 63 g/l (27g/l from baseline) with no sign of haemolysis (Fig 1). All four confirmed COVID-19 patients had automated RBC exchanges as early as possible after PICU admission, which were well tolerated. No patient developed any other organ dysfunctions. Due to expanding knowledge on different forms of COVID-19, it is now common practice to perform CT scans for adults to diagnose patients with no viral excretion. It is not certain if CT scans are as reliable for paediatric patients and for patients with SCD, because of a probable overlap of some radiological findings with sickle cell images.7-9 As to thrombotic risk, ACS in adult patients had already been associated with high risk of thrombosis in the pulmonary arteries but pulmonary thrombosis is also a major concern in COVID-19, both conditions combined might generate an even higher risk for patients. In our usual protocol for ACS, we normally limit RBC transfusion or exchange to the most severe patients with NIV failure or with other sickle cell conditions requiring exchange transfusion, e.g. stroke.6 In patients with COVID-19, we chose aggressive treatments because of the high lethality of COVID-19-related acute respiratory distress syndrome; however, it is possible that our patients would have also had a favourable outcome without this aggressive treatment. Importantly, specific attention must be taken in care-givers’ protection while performing long procedures like RBC exchange for patients with COVID-19. This is the first case series of ACS related to COVID-19 in children. All patients with COVID-19 with ACS received erythrocytapheresis for their ACS with NIV and usual supportive treatment. One patient received tociluzimab. All patients had favourable outcomes. Screening for pulmonary thrombosis might be useful. Future studies are mandatory to determine the best therapeutic options for these patients. The authors thank miss Elisabeth Heilbronner Lahoud for her help in editing the article in English. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Topics & Concepts